DUBLIN, November 23, 2017 /PRNewswire/ --

The "Insulin Pumps (External) - Global Strategic Business Report" report has been added to Research and Markets' offering.

The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Insulin Pumps (External) in US$ Thousand.

The report profiles 15 companies including many key and niche players such as:

• Debiotech S.A.
• F. Hoffmann-La Roche, Ltd.
• Insulet Corp.
• Medtronic Plc.
• Sooil Development Co. Ltd.
• Tandem Diabetes Care Inc.

Key Topics Covered:

1. INDUSTRY OVERVIEW
Insulin Pumps: A Prelude
Key Benefits Offered Infuse Sustained Growth Opportunities
Developed Regions Underpin Sales Growth
The United States
The Largest Market
Europe
A Market with Vast Potential
Lower Current Penetration Leaves Significant Room for Growth
Rising Incidence of Diabetes
A Major Market Driving Factor
Diabetes
Assessing the Economic Burden

2. COMPETITIVE ANALYSIS
Insulin Pumps Market
Set for Interesting Road Ahead
Comparison of Select Durable Insulin Pumps by Manufacturer
Medtronic Banks on New Solutions and Distribution Expansion to Retain Dominance
Tandem Sees Gradual Rise in Market Share
Ypsomed Eyes Brighter Prospects with YpsoPump
Medtrum
A New Entrant with a Strong Product
Competitive Landscape in the Insulin Patch Pump Market
Insulet's OmniPod Benefits from Lack of Close Competition in its League
Insulet Focuses on Advances in Technology and Services to Gain Market Share
Cellnovo's Patch Pump Combines Functionality and Cost- Effectiveness
Valeritas' V-Go
An Affordable Patch Pump for Type II Diabetics
Valeritas Struggles to Push Sales of V-Go
Tough Ground for New Entrants

3. NOTEWORTHY MARKET TRENDS
Type II Diabetes
A Market with Significant Potential
Patch Pumps Gain Manufacturer Attention
Prefilled Insulin Cartridges Gain Popularity over Manual Filling
The Rise of Smart Pumps
A Major Game Changer
Innovative Features Spruce Up the Market for Insulin Pumps
Artificial Pancreas System (APS)
The Future of Diabetes Care
Artificial Pancreas
Are We There Yet?
The Risk of Diabetes in Aging Populace Presents Opportunities for Insulin Pumps
Alarming Rise in Obesity
A Business Case for Diabetes Care
Global Obesity Facts in a Nutshell
Diabetes in Developing Countries to Expand Opportunities

4. KEY MARKET DRIVERS AND CHALLENGES
ICR: A Key Factor to Success
Customer Satisfaction: Crucial to Stay Competitive
Expiry of Warranty Provides New Opportunities to Insulin Pump Makers
Undiagnosed Diabetes
A Key Challenge
Better Safety Review
A Growing Need for Insulin Pumps
Insulin Pump Training
Not Receiving Adequate Attention
Complicated Insulin Pump Software Makes Pump Use Difficult for the Aged
Competition from Other Insulin Delivery Technologies Continues
Implantable Insulin Pumps
A Potential Threat to External Insulin Pumps
Lantus: A Threat to Insulin Pump Manufacturers

5. DIABETES & INSULIN - AN ABSTRACT
Diabetes
A Fatal Disease
Risk Factors for Diabetes
Types of Diabetes
Long Term Complications of Diabetes
Testing Sugar Levels: Easy and Accurate
Insulin
Pancreas: The Main Source of Insulin in Human Body
Types of Insulin
Types of Insulin & Onset of Action
Goal of Insulin Therapy
Insulin Delivery Systems
A. Syringes
B. Insulin Pens
c. Jet Injectors
d. Tablets
e. External Insulin Pumps
f. Artificial Pancreas
Insulin Delivery Technologies

6. PRODUCT OVERVIEW
Evolution of Insulin Pumps
Components of Insulin Pump
How Does an Insulin Pump Work?
Value-added Features of Modern Insulin Pumps
Bolus Calculators
Insulin on Board
Customized Alarms
Touch Bolus
Interface to PCs
Others
Insulin Pump Delivery Rates
Guidelines for Insulin Pump Usage
Advantages
More Accurate and Consistent
Enhances Blood Sugar Control in Pediatric Patients
Adjusting Time Zones While Traveling
Improves Quality of Life
Patient Convenience
Other Advantages
Disadvantages/Risks Involved in the Usage of Insulin Pumps
High Cost
High Involvement
Diabetic Ketoacidosis Risk
Glucose Testing at Regular Intervals
Regular Rotation of Infusion Set
Carrying Back-up Kit
Regular Refilling of Pump
Other Disadvantages

7. PRODUCT INNOVATIONS/INTRODUCTIONS
Medtronic Rolls Out MiniMed 670G System
Tandem Unveils New Software Update for t:slim Insulin Pumps
Tandem Introduces t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration
Tandem Launches t:lock Connector
Tandem Receives US Patent for Infusion Pump and Electronic Device Integration
SOOIL Development Unveils DANA Diabecare RS Insulin Pump
Cellnovo Files FDA 510(k) Clearance for Diabetes Management System
Medtronic Obtains FDA Nod for its New MiniMed 670G System
Medtrum Launches Medtrum P6 Tubeless Insulin Pump
Medtronic Launches MiniMed 630G System
Tandem Secures FDA Expanded Indication for t:slim Insulin Pump
EMA Clears Use of mylife YpsoPump with NovoRapid PumpCart
Animas Receives FDA Expanded Indication for Animas Vibe Insulin Pump in Children
Medtronic Introduces MiniMed Connect System for Insulin Pumps and CGMs
Tandem Gets FDA Nod for t:slim G4 Insulin Pump
Unilife Rolls Out Instant Patch Pumps Platform
Imperium
Medtronic Rolls Out MiniMed 640G System
Tandem Bags FDA Clearance for t:flex Insulin Pump

8. RECENT INDUSTRY ACTIVITY
Animas Decides to Exit Insulin Pump Business
Tandem to Commence At-Home Pivotal Trial for t:slim X2 Insulin Pump
Aspire Capital Fund to Invest in Valeritas Holdings
Roche Diabetes Care Discontinues Accu-Chek Brand in the US
Insulet to Distribute its Omnipod System in Europe
Valeritas Achieves Better Results with V-Go Device
Valeritas Shows Quality Results with V-Go Wearable Device
Medtronic Collaborates with Aetna
Roche to Acquire mySugr
Tandem Announces Order Intake for t:slim X2 Insulin Pump
Bigfoot Secure FDA's Clearance for Artificial Pancreas Trial
Tandem Inks Technology Licensing Deal with TypeZero
Ypsomed and Novo Nordisk Sign Pact for mylife YpsoPump
UnitedHealth Group Selects Medtronic As Exclusive Supplier of Insulin Pumps
Cellnovo and Roche Enter into Commercial Agreement for BGM
Insulet Inks Deal with Mode for Licensing Artificial Pancreas Algorithm
Ypsomed Expands Availability of mylife OmniPod in Europe
Medtronic Enters into Agreement with Chengdu Government to Produce Insulin Pumps
Insulet and Eli Lilly Team Up to Develop New Version of OmniPod for Delivering Lilly's Humalog
Tandem and Dexcom Ink Deal to Pair their Devices
BD Medical and Medtronic Collaborate to Launch New Infusion Set
Bigfoot Biomedical Takes Over Asante Solutions
Debiotech to Take Over Rights to iSense CGM
Medtronic Acquires Covidien

9. FOCUS ON SELECT PLAYERS

10. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 15 (including Divisions/Subsidiaries 18)

• The United States (11)
• Europe (6)
• France (1)
• The United Kingdom (1)
• Rest of Europe (4)
• Asia-Pacific (Excluding Japan) (1)

For more information about this report visit https://www.researchandmarkets.com/research/jb2p3n/insulin_pumps

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets